Home / News / Publications

Publications

Treatment for Macular Telangiectasia Type 2

Charbel Issa P, Kupitz EH, Heeren TF, Holz FG. Dev Ophthalmol. 2016;55:189-95.

Macular Telangiectasia Type 2 Without Clinically Detectable Vasculopathy

Gillies MC, Mehta H, Bird AC. JAMA Ophthalmol. 2015 Aug;133(8):951-4.

Progression of Vision Loss in Macular Telangiectasia Type 2

Heeren TF, Clemons T, Scholl HP, Bird AC, Holz FG, Charbel Issa P. Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3905-12.

Poor long-term outcome of anti-vascular endothelial growth factor therapy in nonproliferative macular telangiectasia type 2

Kupitz EH, Heeren TF, Holz FG, Charbel Issa P. Retina. 2015 Dec;35(12):2619-26.

Ranibizumab for macular telangiectasia type 2 in the absence of subretinal neovascularization

Do DV, Bressler SB, Cassard SD, Gower EW, Tabandeh H, Jefferys JL, Bressler NM. Retina. 2014 Oct;34(10):2063-71.

Macular telangiectasia type 2 (MacTel) in a 34-year-old patient

Nicolai H, Wirix M, Spielberg L, Leys A. BMJ Case Rep. 2014 Sep 23;2014. pii: bcr2014204802.

Choroidal thickness in macular telangiectasia type 2

Chhablani J, Kozak I, Jonnadula GB, Venkata A, Narayanan R, Pappuru RR, Rao PS. Retina. 2014 Sep;34(9):1819-23.

“En face” optical coherence tomography imaging in type 2 idiopathic macular telangiectasia

Wolff B, Basdekidou C, Vasseur V, Sahel JA, Gaudric A, Mauget-Faÿsse M. Retina. 2014 Oct;34(10):2072-8.

Multimodal imaging in type 2 idiopathic macular telangiectasia

Sallo FB, Leung I, Clemons TE, Peto T, Bird AC, Pauleikhoff D. Retina. 2015 Apr;35(4):742-9.

A new CRB1 rat mutation links Müller glial cells to retinal telangiectasia.

Zhao M, Andrieu-Soler C, Kowalczuk L, Paz Cortés M, Berdugo M, Dernigoghossian M, Halili F, Jeanny JC, Goldenberg B, Savoldelli M, El Sanharawi M, Naud MC, van Ijcken W, Pescini-Gobert R, Martinet D, Maass A, Wijnholds J, Crisanti P, Rivolta C, Behar-Cohen F. J Neurosci. 2015 Apr 15;35(15):6093-106. doi: 10.1523/JNEUROSCI.3412-14.2015.